Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years

Bone Marrow Transplantation volume 40, pages 1101–1114 (2007)Cite this article

Abstract

One or two cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation have been shown to improve response rates and survival in myeloma. While this observation has largely been made in patients under the age of 65 years, there is evidence to suggest that the conclusions can be extrapolated to older individuals as well. In contrast to other hematologic malignancies treated with high-dose therapy, autografted myeloma patients continue to relapse several years after transplantation, and few patients are cured with this modality. However, up to a third of patients may be alive beyond a decade; some with excellent quality of life giving rise to the concept of ‘operational cure’. Relapsing disease can be treated with novel agents or repeat high-dose chemotherapy and transplantation. The pressing questions to which answers are not obvious at the moment are whether tandem transplantation should be offered to all patients, and whether novel agents should be used before transplantation or reserved for relapse. Despite their excellent activity, there is no evidence so far that novel agents such as thalidomide, bortezomib and lenalidomide can replace high-dose chemotherapy and stem cell transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.

    Article  CAS  PubMed  Google Scholar 

  2. Singhal S . High-dose therapy and autologous transplantation, In: Mehta J, Singhal S (eds). Myeloma. Martin Dunitz: London, 2002, pp 327–347.

    Google Scholar 

  3. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R . High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.

    CAS  PubMed  Google Scholar 

  4. Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S et al. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? Bone Marrow Transplant 2003; 32: 157–164.

    Article  CAS  PubMed  Google Scholar 

  5. Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S et al. The role of post-transplant maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002; 100: 1641–1647.

    Article  CAS  PubMed  Google Scholar 

  6. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S . High-dose melphalan and autotransplantation followed by post-transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 2004; 33: 1107–1114.

    Article  CAS  PubMed  Google Scholar 

  7. Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant 2005; 36: 19–24.

    Article  CAS  PubMed  Google Scholar 

  8. Powles R, Sirohi B, Treleaven J, Singhal S, Kulkarni S, Lal R et al. Continued first complete remission in multiple myeloma for over 10 years: a series of ‘operationally cured’ patients. Blood (ASH Annual Meeting Abstracts) 2000; 96: Abstract 2215.

  9. Powles R, Singhal S, Sirohi B, Horton C, Treleaven J, Mehta J . Discontinuous complete remission. a new endpoint to evaluate the success of therapy in keeping myeloma patients disease-free for extended periods of time. Blood (ASH Annual Meeting Abstracts) 2001; 98: 166a.

    Google Scholar 

  10. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164.

    Article  PubMed  Google Scholar 

  11. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants multiple myeloma. Blood 1999; 93: 51–54.

    CAS  PubMed  Google Scholar 

  12. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533–539.

    Article  CAS  PubMed  Google Scholar 

  13. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  14. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  15. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50–70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057.

    Article  CAS  PubMed  Google Scholar 

  16. Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–3759.

    Article  PubMed  Google Scholar 

  17. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233.

    Article  CAS  PubMed  Google Scholar 

  18. Child JA . Update on high dose therapy: the MRC Studies, 10th International Myeloma Workshop, Sydney, April 2005. Accessed 21 May 2007 at http://myeloma.org/pdfs/Sydney2005_Child_P8.pdf.

  19. Björkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphoma 1994; 15: 265–272.

    Article  PubMed  Google Scholar 

  20. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997; 20: 435–443.

    Article  CAS  PubMed  Google Scholar 

  21. Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 2000; 25: 483–487.

    Article  CAS  PubMed  Google Scholar 

  22. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  PubMed  Google Scholar 

  23. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144–2151.

    Article  CAS  PubMed  Google Scholar 

  24. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

  25. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929–936.

    Article  CAS  PubMed  Google Scholar 

  26. Singhal S . Treatment of multiple myeloma. BMJ 2003; 327: 575–576.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  PubMed  Google Scholar 

  28. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  CAS  PubMed  Google Scholar 

  29. Cavo M, Cellini C, Zamagni E, Tosi P, Cangini D, Tacchetti P et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2004; 104: Abstract 536.

  30. Cavo M . Double vs single autologous transplantation and role of added thalidomide as primary therapy for multiple myeloma, 10th International Myeloma Workshop, Sydney, April 2005. Accessed 21 May 2007 at http://myeloma.org/pdfs/Sydney2005_Cavo_P8.pdf.

  31. Goldschmidt H . Single vs. double HDT in multiple myeloma: third analysis of the trial GMMG-HD2, 10th International Myeloma Workshop, Sydney, April 2005. Accessed 21 May 2007 at http://myeloma.org/pdfs/Sydney2005_Goldschmidt_P8.pdf.

  32. Fermand JP . MAG studies (1985–2005), 10th International Myeloma Workshop, Sydney, April 2005. Accessed 21 May 2007 at http://myeloma.org/pdfs/Sydney2005_Fermand_P8.pdf.

  33. Sonneveld P, van der Holt B, Vellenga E, Croockewit S, Verhoef G, Segeren C et al. Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 2545.

  34. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887–892.

    Article  CAS  PubMed  Google Scholar 

  35. Sirohi B, Powles R, Mehta J, Kulkarni S, Sankpal S, Treleaven J et al. Prognostic factors at the time of single autotransplantation in 451 myeloma patients treated with 200 mg/m2 melphalan: results equivalent to tadem autotransplantation. Blood (ASH Annual Meeting Abstracts) 2002; 100: Abstract 673.

  36. Abdelkefi A, Ladeb S, Ben Othman T, Torjman L, Lakhal A, Ben Romdhane N et al. Timing of second autologous transplantations in multiple myeloma: results of a multicenter sequential randomized clinical trial. Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 59.

  37. Dimopoulos MA, Hester J, Huh Y, Champlin R, Alexanian R . Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87: 730–734.

    Article  CAS  PubMed  Google Scholar 

  38. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R . Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282.

    CAS  PubMed  Google Scholar 

  39. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J . Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673–679.

    Article  CAS  PubMed  Google Scholar 

  40. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161–167.

    Article  CAS  PubMed  Google Scholar 

  41. Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’? Bone Marrow Transplant 2002; 30: 479–484.

    Article  CAS  PubMed  Google Scholar 

  42. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.

    CAS  PubMed  Google Scholar 

  43. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004; 34: 485–490.

    Article  CAS  PubMed  Google Scholar 

  44. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR . Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436.

    Article  CAS  PubMed  Google Scholar 

  45. Singhal S, Mehta J . Multiple myeloma. Clin J Am Soc Nephrol 2006; 1: 1322–1330.

    Article  CAS  PubMed  Google Scholar 

  46. Kumar S, Lacy MQ, Dispenzieri A, Hayman SR, Rajkumar SV, Zeldenrust S et al. Analysis of outcome after autologous stem transplantation in patients with newly diagnosed myeloma: comparison of different induction regimens. Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 3079.

  47. Zervas K, Mihou D, Katodritou I, Pouli A, Mitsouli CH, Anagnostopoulos A et al. VAD-doxil vs. VAD-doxil plus thalidomide as initial treatment in patients with multiple myeloma: a multicenter randomized trial of the Greek Myeloma Study Group. Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 794.

  48. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    Article  CAS  PubMed  Google Scholar 

  49. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495–502.

    Article  CAS  PubMed  Google Scholar 

  50. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.

    Article  CAS  PubMed  Google Scholar 

  51. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163–3168.

    Article  CAS  PubMed  Google Scholar 

  52. Brinker BT, Waller EK, Leong T, Heffner Jr LT, Redei I, Langston AA et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006; 106: 2171–2180.

    Article  CAS  PubMed  Google Scholar 

  53. Sahebi F, Spielberger R, Kogut NM, Fung H, Falk PM, Parker P et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006; 37: 825–829.

    Article  CAS  PubMed  Google Scholar 

  54. Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs MJ et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10: 8170–8176.

    Article  CAS  PubMed  Google Scholar 

  55. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294.

    Article  CAS  PubMed  Google Scholar 

  56. Powles R, Sirohi B, Kulkarni S, Bhagwati N, Saso R, Raje N et al. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma—a phase I/II feasibility and tolerance study of 17 patients. Bone Marrow Transplant 2000; 25: 949–956.

    Article  CAS  PubMed  Google Scholar 

  57. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 2006; 107: 2633–2638.

    Article  CAS  PubMed  Google Scholar 

  58. Gojo I, Meisenberg B, Guo C, Fassas A, Murthy A, Fenton R et al. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant 2006; 37: 65–72.

    Article  CAS  PubMed  Google Scholar 

  59. Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 2004; 18: 139–145.

    Article  CAS  PubMed  Google Scholar 

  60. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979–983.

    Article  CAS  PubMed  Google Scholar 

  61. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    Article  PubMed  Google Scholar 

  62. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659–2666.

    Article  CAS  PubMed  Google Scholar 

  63. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.

    CAS  PubMed  Google Scholar 

  64. Crowley JJ, McCoy J, LeBlanc M, Barlogie B . Extreme regression: a statistical technique for finding good or poor prognostic groups, illustrated using myeloma patient data from intergroup trial S9321. Blood (ASH Annual Meeting Abstracts) 2004; 102: Abstract 5202.

  65. Sirohi B, Powles R, Mehta J, Treleaven J, Raje N, Kulkarni S et al. The implication of compromised renal function at presentation in myeloma—similar outcome in patients who receive high-dose therapy: A single-center study of 251 previously untreated patients. Med Oncol 2001; 18: 39–50.

    Article  CAS  PubMed  Google Scholar 

  66. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A et al. Glomerular filtration rate prior to high dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001; 85: 325–332.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    Article  CAS  PubMed  Google Scholar 

  68. Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33.

    Article  PubMed  Google Scholar 

  69. Singhal S, Mehta J, Hood S, Mattox S, Siegel D, Fassas A et al. Third transplants for myeloma relapsing after two prior autografts. Blood (ASH Annual Meeting Asbtracts) 1997; 90: 547a.

    Google Scholar 

  70. Singhal S, Mehta J, Desikan K, Siegel D, Singh J, Munshi N et al. Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-α therapy. Bone Marrow Transplant 1999; 24: 13–17.

    Article  CAS  PubMed  Google Scholar 

  71. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–3779.

    Article  CAS  PubMed  Google Scholar 

  72. Jantunen E, Kuittinen T, Penttilä K, Lehtonen P, Mahlamäki E, Nousiainen T . High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006; 37: 917–922.

    Article  CAS  PubMed  Google Scholar 

  73. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

    Article  CAS  PubMed  Google Scholar 

  74. Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99–04 protocol. Blood 2006; 107: 397–403.

    Article  CAS  PubMed  Google Scholar 

  75. Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971–977.

    Article  CAS  PubMed  Google Scholar 

  76. Reece DE, Flomenberg N, Badros A, Phillips GL, Filicko J, Howard DS et al. Update of melphalan 280 mg/m2 plus amifostine cytoprotection before autologous stem cell transplantation as part of initial therapy in multiple myeloma patients. J Clin Oncol (ASCO Annual Meeting Proceedings) 2006; 24: Abstract 7608.

  77. Singhal S, Powles R, Milan S, Raje N, Viner C, Treleaven J et al. Clearance of paraprotein after autografting for multiple myeloma. Bone Marrow Transplant 1995; 16: 537–540.

    CAS  PubMed  Google Scholar 

  78. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  PubMed  Google Scholar 

  79. Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  PubMed  Google Scholar 

  80. Sirohi B, Powles R, Kulkarni S, Carr-Smith HD, Patel G, Das M et al. Serum free light chain assessment in myeloma patients who are in complete remission (CR) by immunofixation predicts early relapse. Blood (ASH Annual Meeting Abstracts) 2003; 102: Abstract 5195.

  81. Singhal S, Stein R, Vickrey E, Mehta J . The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007; 109: 3611–3612.

    Article  CAS  PubMed  Google Scholar 

  82. Singhal S, Mehta J . Treatment of relapsed and refractory multiple myeloma. Curr Treatment Options Oncol 2003; 4: 229–237.

    Article  Google Scholar 

  83. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B . Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7–11.

    CAS  PubMed  Google Scholar 

  84. Mehta J, Singhal S . Graft-versus-myeloma. Bone Marrow Transplant 1998; 22: 835–843.

    Article  CAS  PubMed  Google Scholar 

  85. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494.

    Article  CAS  PubMed  Google Scholar 

  86. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    Article  CAS  PubMed  Google Scholar 

  87. Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau JL, Dmoszynska A . Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma: results of a phase 3 study (MM-010). Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 6.

  88. Singhal S, Mehta J . Lenalidomide in myeloma. Curr Treatment Options Oncol 2007; (in press).

  89. Rajkumar SV, Dingli D, Nowakowski G, Gertz M, Lacy MQ, Dispenzieri A et al. Thalidomide and dexamethasone in newly diagnosed multiple myeloma: long-term results in patients not undergoing upfront autologous stem cell transplantation. J Clin Oncol (ASCO Annual Meeting Proceedings) 2005; 23: Abstract 6632.

    Google Scholar 

  90. Anderson K, Richardson P, Chanan-Khan A, Schlossman R, Munshi N, Oaklander A et al. Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study. J Clin Oncol (ASCO Annual Meeting Proceedings) 2006; 24: Abstract 7504.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

    J Mehta & S Singhal

Authors
  1. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Mehta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mehta, J., Singhal, S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 40, 1101–1114 (2007). https://doi.org/10.1038/sj.bmt.1705799

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705799

Keywords

This article is cited by

Search

Advanced search

Quick links